The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Enzyme replacement and enhancement therapies for lysosomal diseases
Abstract
Summary: Although first suggested by de Duve in 1964, enzyme replacement therapy (ERT) for lysosomal storage diseases did not become a reality until the early 1990s when its safety and effectiveness were demonstrated in type 1 Gaucher disease. Today, ERT is a reality for Gaucher disease, Fabry disease and mucopolysaccharidosis type I (MPS I), and clinical trials with recombinant human enzymes are ongoing in Pompe disease, MPS II and MPS VI, and are about to begin in Neimann–Pick B disease. In addition to ERT, enzyme enhancement therapy (EET) offers a novel therapeutic strategy to increase the residual function of mutant proteins. EET employs small molecules as 'pharmacological chaperones' to rescue misfolded and/or unstable mutant enzymes or proteins that have residual function. EET also offers the possibility of treating neurodegenerative lysosomal disorders since these small therapeutic molecules may cross the blood–brain barrier. The current status of ERT and the prospects for EET for lysosomal storage diseases are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896 · cited 2×
“A clear need for each of these diseases will be the identi¢cation and monitoring of biomarkers that will assess disease progression or improvement, analogous to the use of chitotriosidase activity in type 1 Gaucher disease (Aguilera et al 2003; Hollak et al 1994; Young et al 1997).”
MethodDissecting glycoprotein quality control in the secretory pathway
Cabral, C. M., Liu, Y., & Sifers, R. N. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01942-9 · Cited by 230
Cited by
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Hughes, D. A., Nicholls, K., Shankar, S. P., Sunder-Plassmann, G., Koeller, D., Nedd, K., Vockley, G., Hamazaki, T., Lachmann, R., Ohashi, T., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104178 · Cited by 386
Sphingolipid metabolism diseases
Kolter, T., & Sandhoff, K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.05.027 · Cited by 367
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
Ron, I., & Horowitz, M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi240 · Cited by 330
Vellodi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05293.x · Cited by 295
Metadata
- Authors
- Desnick, R. J.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2004-05
- Volume
- 27
- Issue
- 3
- Pages
- 385-410
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2074616175
- Cited by
- 222
- References
- 3
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enzyme replacement and enhancement therapies for lysosomal diseases. https://app.cochat.ai/papers/10.1023/b:boli.0000031101.12838.c6
- The paper
- Desnick, R. J. (2004). Enzyme replacement and enhancement therapies for lysosomal diseases. Journal of Inherited Metabolic Disease. https://doi.org/10.1023/b%3Aboli.0000031101.12838.c6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.